In response to “outcomes of patients with inflammatory breast cancer treated by breast conserving surgery”: the argument against breast conservation and sentinel lymph node biopsy in IBC
- 290 Downloads
In October 2016, Brzezinska et al. advocated for the use of breast conservation therapy (BCT) in select patients with inflammatory breast cancer (IBC) . Thirty-five patients who were diagnosed with IBC from 1999 to 2013 and treated with BCT were reviewed from a prospectively collected database. All patients had a localized solid tumor component in the breast and were treated with trimodality therapy: neoadjuvant therapy, surgery, and adjuvant radiation. They were selected to undergo breast-conserving surgery at the discretion of the multidisciplinary treatment team if the erythema and characteristic peau d’orange resolved following neoadjuvant therapy. Surgical management consisted of segmental mastectomy with axillary staging in most of the cases. Management of the axilla included axillary lymph node dissection in 20 patients, sentinel lymph node dissection (SLND) in 14 patients (resulting in completion ALND in four patients), and axillary radiation alone in one patient. SLN...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Rea D, Francis A, Hanby AM et al (2015) Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer 112(9):1613–1615. doi: 10.1038/bjc.2015.115 Epub 2015 Mar 31 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30(32):3960–3966. doi: 10.1200/JCO.2011.40.8369 Epub 2012 Oct 1 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (version 2.2017). www.nccn.org. Accessed 15 Jan 2017
- 18.Gianni L, Eiermann W, Semiglazov V et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647. doi: 10.1016/S1470-2045(14)70080-4 CrossRefPubMedGoogle Scholar